Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

Data presented during “Acute Kidney Injury” symposium at the American Society for Nephrology 2019 Annual Meeting

Toronto, Canada December 2,2019

Mannin Research Inc.’s (Mannin) Chief Scientific Officer, Dr. Susan Quaggin, presented positive data on a potential new treatment for acute kidney injury (AKI), during the annual Kidney Week meeting, in Washington DC in November 2019.

The data suggests that the Angiopoietin-Tie2 signaling pathway is a promising therapeutic target to prevent AKI after ischemia caused by ischemia–reperfusion injury to the kidney. Ischemia in the kidney occurs in a range of clinically important scenarios such as hypotension, sepsis, and cardiovascular events such as strokes.

Mannin along with its academic research partners have previously shown that therapeutics activating the receptor protein kinase Tie2 has the potential to treat glaucoma, however its role in acute kidney injury has not been studied. The presented data shows the potential for therapeutics to protect kidneys from acute injury. The Angiopoietin-Tie2 signaling pathway has been connected to various vascular diseases including glaucoma, diabetic nephropathy, and acute kidney injury.

Acute kidney injury (AKI) leads to decreased kidney function and induces a generalized inflammatory response that affects distant organs. Full recovery of kidney function is uncommon, which leaves these patients at risk of long-term morbidity and death[i].

Worldwide 1 in 5 adults will be affected by AKI during their hospitalization stay, in addition, AKI-associated mortality rates are around 24% in adults[ii]. Current treatments for AKI are mainly supportive and do not treat the underlying condition[iii].

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


[i] Hoste, Eric A. J. et al. “Global Epidemiology And Outcomes Of Acute Kidney Injury”. Nature Reviews Nephrology, vol 14, no. 10, 2018, pp. 607-625. Springer Science And Business Media LLC, doi:10.1038/s41581-018-0052-0. Accessed 28 Nov 2019.

[ii] Susantitaphong, Paweena et al. “World Incidence Of AKI: A Meta-Analysis”. Clinical Journal Of The American Society Of Nephrology, vol 8, no. 9, 2013, pp. 1482-1493. American Society Of Nephrology (ASN), doi:10.2215/cjn.00710113. Accessed 28 Nov 2019.

[iii] Levey, Andrew S., and Matthew T. James. “Acute Kidney Injury”. Annals Of Internal Medicine, vol 167, no. 9, 2017, p. ITC66. American College Of Physicians, doi:10.7326/aitc201711070. Accessed 7 Nov 2019.